Joseph Thome
Stock Analyst at TD Cowen
(1.38)
# 3,583
Out of 5,090 analysts
19
Total ratings
37.5%
Success rate
-7.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Hold | $50 → $63 | $77.26 | -18.45% | 3 | Nov 5, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $10 | $5.98 | +67.22% | 1 | Oct 31, 2025 | |
| MIRM Mirum Pharmaceuticals | Initiates: Buy | $95 | $68.48 | +38.73% | 1 | Sep 24, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $80.50 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $32.02 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $489.31 | -18.25% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $29.50 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $29.52 | +15.18% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $3.74 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $1.78 | - | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $45.01 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.37 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $149.22 | -12.88% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.61 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.34 | - | 1 | Nov 23, 2021 |
PTC Therapeutics
Nov 5, 2025
Maintains: Hold
Price Target: $50 → $63
Current: $77.26
Upside: -18.45%
Ardelyx
Oct 31, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $5.98
Upside: +67.22%
Mirum Pharmaceuticals
Sep 24, 2025
Initiates: Buy
Price Target: $95
Current: $68.48
Upside: +38.73%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $80.50
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $32.02
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $489.31
Upside: -18.25%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $29.50
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $29.52
Upside: +15.18%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $3.74
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.78
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $45.01
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.37
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $149.22
Upside: -12.88%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $9.61
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.34
Upside: -